Frontline treatment of localized osteosarcoma without methotrexate-Reference-Cited by-同舟云学术

Frontline treatment of localized osteosarcoma without methotrexate

Published:2011-01-10 Issue:12 Volume:117 Page:2770-2778
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Daw Najat C.,Neel Michael D.,Rao Bhaskar N.,Billups Catherine A.,Wu Jianrong,Jenkins Jesse J.,Quintana Juan,Luchtman-Jones Lori,Villarroel Milena,Santana Victor M.

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.25715/fullpdf

Reference35 articles.

1. Osteogenic sarcoma with clinically detectable metastasis at initial presentation;Meyers;J Clin Oncol.,1993

2. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols;Bielack;J Clin Oncol.,2002

3. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate;Meyers;J Clin Oncol.,2005

4. Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs;Fuchs;Ann Oncol.,1998

5. Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651;Goorin;J Clin Oncol.,2003

Cited by 86 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long term survival in adult osteosarcoma patients treated with a two-drug regimen: Final results of the OSAD93 phase II study of the FSG-GETO;European Journal of Cancer;2024-09

2. Prognostic factors in high-grade pediatric osteosarcoma among children and young adults: Greek Nationwide Registry for Childhood Hematological Malignancies and Solid Tumors (NARECHEM-ST) data along with a systematic review and meta-analysis;Cancer Epidemiology;2024-06

3. Cyclovirobuxine D inhibits the growth of osteosarcoma cells through the induction of autophagy flux arrest by promoting lysosomal acidification;Journal of Functional Foods;2024-05

4. European standard clinical practice recommendations for children and adolescents with primary and recurrent osteosarcoma;EJC Paediatric Oncology;2023-12

5. Favorable treatment response to high‐grade sarcoma in neurofibromatosis 1;Pediatric Blood & Cancer;2023-06-19